{"id":"NCT03334422","sponsor":"Eli Lilly and Company","briefTitle":"Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-27","primaryCompletion":"2018-12-12","completion":"2018-12-12","firstPosted":"2017-11-07","resultsPosted":"2020-01-22","lastUpdate":"2020-01-22"},"enrollment":615,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Baricitinib","otherNames":["LY3009104"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"4 Milligram (mg) Baricitinib","type":"EXPERIMENTAL"},{"label":"2mg Baricitinib","type":"EXPERIMENTAL"},{"label":"1mg Baricitinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.","primaryOutcome":{"measure":"Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a â‰¥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib)","timeFrame":"16 Weeks","effectByArm":[{"arm":"Placebo","deltaMin":4.5,"sd":null},{"arm":"2mg Baricitinib","deltaMin":10.6,"sd":null},{"arm":"4mg Baricitinib","deltaMin":13.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.026"},{"comp":"OG000 vs OG002","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":80,"countries":["Argentina","Australia","Austria","Hungary","Israel","Japan","Poland","South Korea","Spain","Switzerland"]},"refs":{"pmids":["36255569","34688290","34275122","33899152","33826132","33222559"],"seeAlso":["https://www.lillytrialguide.com/en-US/studies/eczema/JAHM#?postal="]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":244},"commonTop":["Nasopharyngitis","Headache","Herpes simplex","Blood creatine phosphokinase increased"]}}